The U.S. Food and Drug Administration has made it pointedly clear that they are looking to expedite the approval of drugs in areas of high-need, such as that of brain cancer. Janet Woodcock, director for the Center for Drug Evaluation and Research at the FDA, said a week ago that the regulatory agency is considering approving some drugs after JUST ONE Phase I clinical trial if they can show substantial impact in areas of great unmet medical need.
Market Data 
Markets 
AI
